BriaCell Therapeutics Corp.
BCTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.44
KIRA · Stoqly’s AI analyst, in plain words
- BriaCell Therapeutics Corp. lost $26.3M in fiscal 2025.
Market cap
$24.9M
P/E
1.5x
Revenue
—
Net income
−$26.3M
Free cash flow
—
Operating margin
—
BriaCell Therapeutics Corp. in 30 seconds · fiscal 2025
Does it make a profit?
−$26.3M
No. It lost money last year.
How is the share priced?
1.5x
One share costs 1.5 times its yearly profit per share.
What BriaCell Therapeutics Corp. does
No business description yet.
- Fiscal year ends
- July 31, 2025
- Latest annual report
- 10-K · Oct 16, 2025
- Legal name
- BriaCell Therapeutics Corp.
- CIK
- 0001610820
BriaCell Therapeutics Corp. · BCTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$13.8M | −$26.8M | −$20.3M | −$4.8M | −$26.3M |
| Diluted EPS | — | −$1.73 | −$1.30 | −$43.68 | −$62.19 |
| Cash | |||||
| Cash from operations | −$7.8M | −$12.5M | −$23.7M | −$24.1M | −$28.2M |
| Capital expenditure | — | — | — | $0.5M | — |
| Free cash flow | — | — | — | −$24.6M | — |
| Share count change | — | — | 0.8% | −99.3% | 285.7% |
| Debt and strength | |||||
| Cash and short-term investments | $57.3M | $41.0M | $21.3M | $0.9M | $17.9M |
| Shareholders' equity | $27.7M | $10.3M | −$3.8M | −$2.7M | $17.3M |
| Current ratio | 103.8x | 45.0x | 15.0x | 0.5x | 5.0x |
| Interest coverage | −88.8x | −15,288.9x | — | — | −735.3x |
| Returns and quality | |||||
| Return on equity | −49.9% | −141.3% | −619.8% | — | −359.2% |
| Return on tangible equity | −50.4% | −265.8% | — | — | −153.4% |
| Altman Z'' | 5.0 | −0.3 | −9.5 | −90.2 | −16.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BriaCell Therapeutics Corp. · BCTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.44 a share, the company is worth $24.9M: 1.5 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001610820). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.